Clinical Trial Detail

NCT ID NCT02883049
Title Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Recruitment Suspended
Gender both
Phase Phase III
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

precursor B lymphoblastic lymphoma/leukemia

Therapies

Dasatinib

Dexamethasone + Doxorubicin

Prednisone

Vincristine

Thioguanine

Cytarabine

Mercaptopurine

Leucovorin

Methotrexate

Pegaspargase

Etoposide

Clofarabine

Age Groups: adult child

Additional content available in CKB BOOST